165 related articles for article (PubMed ID: 19074639)
1. Liquiritigenin, a flavonoid aglycone from licorice, has a choleretic effect and the ability to induce hepatic transporters and phase-II enzymes.
Kim YW; Kang HE; Lee MG; Hwang SJ; Kim SC; Lee CH; Kim SG
Am J Physiol Gastrointest Liver Physiol; 2009 Feb; 296(2):G372-81. PubMed ID: 19074639
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats with acute hepatitis induced by d-galactosamine/lipopolysaccharide or CCl(4).
Kang HE; Kim YW; Sohn SI; Baek SR; Lee JW; Kim SG; Lee I; Lee MG
Xenobiotica; 2010 Jun; 40(6):424-36. PubMed ID: 20350053
[TBL] [Abstract][Full Text] [Related]
3. Boldine enhances bile production in rats via osmotic and farnesoid X receptor dependent mechanisms.
Cermanova J; Kadova Z; Zagorova M; Hroch M; Tomsik P; Nachtigal P; Kudlackova Z; Pavek P; Dubecka M; Ceckova M; Staud F; Laho T; Micuda S
Toxicol Appl Pharmacol; 2015 May; 285(1):12-22. PubMed ID: 25771127
[TBL] [Abstract][Full Text] [Related]
4. Genipin enhances Mrp2 (Abcc2)-mediated bile formation and organic anion transport in rat liver.
Shoda J; Miura T; Utsunomiya H; Oda K; Yamamoto M; Kano M; Ikegami T; Tanaka N; Akita H; Ito K; Suzuki H; Sugiyama Y
Hepatology; 2004 Jan; 39(1):167-78. PubMed ID: 14752835
[TBL] [Abstract][Full Text] [Related]
5. Biliary excretion of pravastatin and taurocholate in rats with bile salt export pump (Bsep) impairment.
Cheng Y; Freeden C; Zhang Y; Abraham P; Shen H; Wescott D; Humphreys WG; Gan J; Lai Y
Biopharm Drug Dispos; 2016 Jul; 37(5):276-86. PubMed ID: 27059119
[TBL] [Abstract][Full Text] [Related]
6. Resveratrol effectively attenuates α-naphthyl-isothiocyanate-induced acute cholestasis and liver injury through choleretic and anti-inflammatory mechanisms.
Wang T; Zhou ZX; Sun LX; Li X; Xu ZM; Chen M; Zhao GL; Jiang ZZ; Zhang LY
Acta Pharmacol Sin; 2014 Dec; 35(12):1527-36. PubMed ID: 25418378
[TBL] [Abstract][Full Text] [Related]
7. Inchinkoto, a herbal medicine, and its ingredients dually exert Mrp2/MRP2-mediated choleresis and Nrf2-mediated antioxidative action in rat livers.
Okada K; Shoda J; Kano M; Suzuki S; Ohtake N; Yamamoto M; Takahashi H; Utsunomiya H; Oda K; Sato K; Watanabe A; Ishii T; Itoh K; Yamamoto M; Yokoi T; Yoshizato K; Sugiyama Y; Suzuki H
Am J Physiol Gastrointest Liver Physiol; 2007 May; 292(5):G1450-63. PubMed ID: 17038627
[TBL] [Abstract][Full Text] [Related]
8. A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Morgan RE; van Staden CJ; Chen Y; Kalyanaraman N; Kalanzi J; Dunn RT; Afshari CA; Hamadeh HK
Toxicol Sci; 2013 Nov; 136(1):216-41. PubMed ID: 23956101
[TBL] [Abstract][Full Text] [Related]
9. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
[TBL] [Abstract][Full Text] [Related]
10. Liquiritigenin pharmacokinetics in a rat model of diabetes mellitus induced by streptozotocin: greater formation of glucuronides in the liver, especially M2, due to increased hepatic uridine 5'-diphosphoglucuronic acid level.
Kang HE; Sohn SI; Baek SR; Lee JW; Lee MG
Metabolism; 2010 Oct; 59(10):1472-80. PubMed ID: 20170928
[TBL] [Abstract][Full Text] [Related]
11. LPS-induced downregulation of MRP2 and BSEP in human liver is due to a posttranscriptional process.
Elferink MG; Olinga P; Draaisma AL; Merema MT; Faber KN; Slooff MJ; Meijer DK; Groothuis GM
Am J Physiol Gastrointest Liver Physiol; 2004 Nov; 287(5):G1008-16. PubMed ID: 15205115
[TBL] [Abstract][Full Text] [Related]
12. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of liquiritigenin and its two glucuronides, M1 and M2, in rats.
Kang HE; Sohn SI; Baek SR; Lee JW; Lee MG
J Pharm Pharmacol; 2011 Jan; 63(1):49-57. PubMed ID: 21155815
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol attenuates lipopolysaccharide-induced hepatitis in D-galactosamine sensitized rats: role of nitric oxide synthase 2 and heme oxygenase-1.
Farghali H; Cerný D; Kameníková L; Martínek J; Horínek A; Kmonícková E; Zídek Z
Nitric Oxide; 2009; 21(3-4):216-25. PubMed ID: 19796704
[TBL] [Abstract][Full Text] [Related]
14. Tacrine, an oral acetylcholinesterase inhibitor, induced hepatic oxidative damage, which was blocked by liquiritigenin through GSK3-beta inhibition.
Park SM; Ki SH; Han NR; Cho IJ; Ku SK; Kim SC; Zhao RJ; Kim YW
Biol Pharm Bull; 2015; 38(2):184-92. PubMed ID: 25747977
[TBL] [Abstract][Full Text] [Related]
15. Anticholestatic mechanisms of ursodeoxycholic acid in lipopolysaccharide-induced cholestasis.
Razori MV; Maidagan PM; Ciriaci N; Andermatten RB; Barosso IR; Martín PL; Basiglio CL; Sánchez Pozzi EJ; Ruiz ML; Roma MG
Biochem Pharmacol; 2019 Oct; 168():48-56. PubMed ID: 31202734
[TBL] [Abstract][Full Text] [Related]
16. Up-regulation of BSEP and MRP2 by Calculus Bovis administration in 17α-ethynylestradiol-induced cholestasis: Involvement of PI3K/Akt signaling pathway.
Wu T; Zhang Q; Li J; Chen H; Wu J; Song H
J Ethnopharmacol; 2016 Aug; 190():22-32. PubMed ID: 27237619
[TBL] [Abstract][Full Text] [Related]
17. Ticlopidine, a cholestatic liver injury-inducible drug, causes dysfunction of bile formation via diminished biliary secretion of phospholipids: involvement of biliary-excreted glutathione-conjugated ticlopidine metabolites.
Yoshikado T; Takada T; Yamamoto H; Tan JK; Ito K; Santa T; Suzuki H
Mol Pharmacol; 2013 Feb; 83(2):552-62. PubMed ID: 23220748
[TBL] [Abstract][Full Text] [Related]
18. Enhanced expressions and activations of leukotriene C4 synthesis enzymes in D-galactosamine/lipopolysaccharide-induced rat fulminant hepatic failure model.
Ma KF; Yang HY; Chen Z; Qi LY; Zhu DY; Lou YJ
World J Gastroenterol; 2008 May; 14(17):2748-56. PubMed ID: 18461660
[TBL] [Abstract][Full Text] [Related]
19. Lack of biliary lipid excretion in the little skate, Raja erinacea, indicates the absence of functional Mdr2, Abcg5, and Abcg8 transporters.
Elferink RP; Ottenhoff R; Fricker G; Seward DJ; Ballatori N; Boyer J
Am J Physiol Gastrointest Liver Physiol; 2004 May; 286(5):G762-8. PubMed ID: 14701720
[TBL] [Abstract][Full Text] [Related]
20. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724,714.
Feng B; Xu JJ; Bi YA; Mireles R; Davidson R; Duignan DB; Campbell S; Kostrubsky VE; Dunn MC; Smith AR; Wang HF
Toxicol Sci; 2009 Apr; 108(2):492-500. PubMed ID: 19223659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
